Drugs / Octagam 10%
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00812565 | Feb 2009 → Sep 2010 | Alzheimer disease | Octapharma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04400058 | Jun 2020 → Feb 2022 | COVID-19 | Octapharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octagam 10% | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04400058 ↗ |
| Modality | Protein / enzyme biologic | “octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.” NCT00812565 ↗ |
| Route | Intravenous | “Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).” NCT00812565 ↗ |